Across TCGA pan-cancer cohorts, MIB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MIB2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MIB2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MIB2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where MIB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.902	0.788	.010	21	view →
CCRCC	DFS	Quartile	II,III,IV	0.906	0.339	.004	8	view →
PDAC	DFS	Quartile	III,IV	0.304	0.630	.035	5	view →
LUAD	DFS	Quartile	All	0.754	0.956	.030	4	view →
LSCC	OS	Median	II,III,IV	0.880	1.000	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MIB2 tumor-vs-normal RNA expression · all MIB2 data types